A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders

The American Journal of Psychiatry
Magali ReyesMarielle Eerdekens

Abstract

The authors compared the effects of maintenance versus withdrawal of risperidone treatment in children and adolescents with symptoms of disruptive behavior disorder. Patients with disruptive behavior disorder (5-17 years of age and a range of intellect) who had responded to risperidone treatment over 12 weeks were randomly assigned to 6 months of double-blind treatment with either risperidone or placebo. The primary efficacy measure was time to symptom recurrence, defined as sustained deterioration on either the Clinical Global Impression severity rating (/2 points) or the conduct problem subscale of the Nisonger Child Behavior Rating Form (/7 points). Secondary efficacy measures included rates of discontinuation due to symptom recurrence, disruptive behavior disorder symptoms, and general function. Safety and tolerability were also assessed. Risperidone dosage was based on weight (patients <50 kg: 0.25-0.75 mg/day; patients /50 kg: 0.5-1.5 mg/day). Treatment was initiated in 527 patients, with 335 randomly assigned to a double-blind maintenance condition. Time to symptom recurrence was significantly longer in patients who continued risperidone treatment than in those switched to placebo. Symptom recurrence in 25% of patients o...Continue Reading

Citations

Oct 5, 2006·Journal of Autism and Developmental Disorders·Gahan J PandinaFiona Dunbar
Dec 6, 2012·Journal of Autism and Developmental Disorders·Justine M KentDavid Hough
Mar 9, 2007·Journal of Child and Adolescent Psychopharmacology·Robert L FindlingNora K McNamara
Jun 14, 2006·Journal of Child and Adolescent Psychopharmacology·Magali ReyesMarielle Eerdekens
Sep 2, 2008·Journal of Child and Adolescent Psychopharmacology·Magali HaasGahan J Pandina
Dec 29, 2009·Journal of Child and Adolescent Psychopharmacology·Magali HaasStuart F Kushner
Dec 29, 2009·Journal of Child and Adolescent Psychopharmacology·Gahan J PandinaBarbara Cornblatt
Nov 3, 2009·Journal of Child and Adolescent Psychopharmacology·Margaret WeissRebecca Harrison
Jun 15, 2011·Journal of Child and Adolescent Psychopharmacology·Fernanda Valle KriegerLuis Augusto Rohde
Dec 27, 2011·Journal of Child and Adolescent Psychopharmacology·Elizabeth PappadopulosPeter S Jensen
Dec 6, 2011·Journal of Child and Adolescent Psychopharmacology·Tamara PringsheimScott B Patten
Nov 5, 2011·Journal of Paediatrics and Child Health·Michael J DuhigJames G Scott
Aug 9, 2007·Child and Adolescent Psychiatry and Mental Health·Gahan J PandinaGeorges M Gharabawi
Apr 15, 2011·Child and Adolescent Psychiatry and Mental Health·Eyup S ErcanBurcu Ozbaran
May 31, 2012·Child and Adolescent Psychiatry and Mental Health·Chadi Albert CalargeBridget Zimmerman
Jun 9, 2012·Child and Adolescent Psychiatry and Mental Health·Gahan PandinaMagali Haas
Jun 28, 2006·CNS Drugs·Oleg V Tcheremissine, Lori M Lieving
Apr 15, 2014·Journal of Child and Adolescent Psychopharmacology·Chadi A CalargeTrudy L Burns
Feb 3, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Magali HaasVivek Kusumakar
Apr 4, 2008·International Review of Psychiatry·Drew H Barzman, Robert L Findling
Oct 6, 2006·Expert Opinion on Pharmacotherapy·Suad Kapetanovic, George M Simpson
Jul 15, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Tamara PringsheimScott Patten
May 10, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alessandro ZuddasTatiana Usala
Feb 8, 2011·Research in Developmental Disabilities·Jill A Hollway, Michael G Aman
Mar 11, 2010·Journal of the American Academy of Child and Adolescent Psychiatry·Mark OlfsonTobias Gerhard
Nov 22, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Mary Margaret GleasonCharles H Zeanah
Mar 7, 2009·Child and Adolescent Psychiatric Clinics of North America·Gagan Joshi, Timothy Wilens
Mar 3, 2009·The Psychiatric Clinics of North America·Molly McVoy, Robert Findling
Feb 23, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Peter S JensenBenedetto Vitiello
May 29, 2015·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·J ReekieM A Sabin
Jan 21, 2011·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Clement C ZaiJoseph H Beitchman
Mar 19, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Jiamei LianChao Deng
Nov 29, 2011·Research in Developmental Disabilities·Johnny L MatsonMichael L Matson
Dec 20, 2014·Journal of the American Academy of Child and Adolescent Psychiatry·Karsten Gjessing JensenAnne Katrine Pagsberg
Apr 12, 2016·Academic Pediatrics·Lisa L Giles, D Richard Martini

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Software Mentioned

SAS

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Related Papers

The American Journal of Psychiatry
Robert L FindlingRisperidone Disruptive Behavior Study Group
Journal of the American Academy of Child and Adolescent Psychiatry
Richard SnyderRisperidone Conduct Study Group
The American Journal of Psychiatry
Research Units on Pediatric Psychopharmacology Autism Network
Journal of the American Academy of Child and Adolescent Psychiatry
Jan CroonenberghsRisperidone Disruptive Behavior Study Group
© 2021 Meta ULC. All rights reserved